Company registration number 13878327 (England and Wales)
RENEWVAX LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
PAGES FOR FILING WITH REGISTRAR
RENEWVAX LIMITED
COMPANY INFORMATION
Directors
Dr N D Murray
Dr S Cruwys
Dr C Horrocks
Company number
13878327
Registered office
Liverpool Science Park
131 Mount Pleasant
Liverpool
L3 5TF
Accountants
Fairhurst Accountants Ltd
Douglas Bank House
Wigan Lane
Wigan
Lancashire
WN1 2TB
RENEWVAX LIMITED
CONTENTS
Page
Statement of financial position
1
Notes to the financial statements
2 - 4
RENEWVAX LIMITED
STATEMENT OF FINANCIAL POSITION
As At 31 December 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
3
23,075
-
0
Current assets
Debtors
4
69,540
30,153
Cash at bank and in hand
236,865
175,605
306,405
205,758
Creditors: amounts falling due within one year
5
(66,836)
(46,131)
Net current assets
239,569
159,627
Net assets
262,644
159,627
Capital and reserves
Called up share capital
126
101
Share premium account
1,189,935
689,960
Profit and loss reserves
(927,417)
(530,434)
Total equity
262,644
159,627

For the financial year ended 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the income statement within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 8 May 2026 and are signed on its behalf by:
Dr N D Murray
Director
Company registration number 13878327 (England and Wales)
RENEWVAX LIMITED
NOTES TO THE FINANCIAL STATEMENTS
For The Year Ended 31 December 2025
- 2 -
1
Accounting policies
Company information

Renewvax Limited is a private company limited by shares incorporated in England and Wales. The registered office is Liverpool Science Park, 131 Mount Pleasant, Liverpool, L3 5TF.

1.1
Basis of preparation

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

1.2
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Lab equipment
25% on Reducing Balance
Computer and office equipment
25% on Reducing Balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.3
Financial instruments

The company only holds basic financial instruments, as defined under Section 11 of FRS 102.

 

Trade and other debtors are initially recognised at the transaction price and thereafter stated at amortised cost using the effective interest method, less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases, the receivables are stated at cost less impairment losses for bad and doubtful debts.

 

Short term financial liabilities, including trade and other creditors, overdrafts and related party loans, are measured at transaction price. Financial liabilities that have no stated interest rate and are payable within one year shall be measured at the undiscounted amount due, those payable after one year should be measured at amortised cost, using the effective interest rate method.

1.4
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

RENEWVAX LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
For The Year Ended 31 December 2025
1
Accounting policies
(Continued)
- 3 -
1.5
Retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
3
2
3
Tangible fixed assets
Lab equipment
Computer and office equipment
Total
£
£
£
Cost
At 1 January 2025
-
0
-
0
-
0
Additions
21,318
5,588
26,906
At 31 December 2025
21,318
5,588
26,906
Depreciation and impairment
At 1 January 2025
-
0
-
0
-
0
Depreciation charged in the year
3,118
713
3,831
At 31 December 2025
3,118
713
3,831
Carrying amount
At 31 December 2025
18,200
4,875
23,075
At 31 December 2024
-
0
-
0
-
0
4
Debtors
2025
2024
Amounts falling due within one year:
£
£
Other debtors
69,540
30,153
RENEWVAX LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
For The Year Ended 31 December 2025
- 4 -
5
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
57,883
39,760
Taxation and social security
2,853
-
0
Other creditors
6,100
6,371
66,836
46,131
6
Operating lease commitments
As lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2025
2024
£
£
Total commitments
15,222
-
0
7
Related party transactions

During the year the company was charged expenses amounting to £71,075 (2024: £41,913) by certain directors and their spouse.

 

At the year end £Nil (2024: £2,000) expenses remained outstanding.

 

2025-12-312025-01-01falsefalsefalse08 May 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityDr N D MurrayMs M O'BrienDr S CruwysDr C Horrocks138783272025-01-012025-12-3113878327bus:Director12025-01-012025-12-3113878327bus:Director32025-01-012025-12-3113878327bus:Director42025-01-012025-12-3113878327bus:Director22025-01-012025-12-3113878327bus:RegisteredOffice2025-01-012025-12-31138783272025-12-31138783272024-12-3113878327core:PlantMachinery2025-12-3113878327core:ComputerEquipment2025-12-3113878327core:PlantMachinery2024-12-3113878327core:ComputerEquipment2024-12-3113878327core:CurrentFinancialInstrumentscore:WithinOneYear2025-12-3113878327core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3113878327core:CurrentFinancialInstruments2025-12-3113878327core:CurrentFinancialInstruments2024-12-3113878327core:ShareCapital2025-12-3113878327core:ShareCapital2024-12-3113878327core:SharePremium2025-12-3113878327core:SharePremium2024-12-3113878327core:RetainedEarningsAccumulatedLosses2025-12-3113878327core:RetainedEarningsAccumulatedLosses2024-12-3113878327core:PlantMachinery2025-01-012025-12-3113878327core:ComputerEquipment2025-01-012025-12-31138783272024-01-012024-12-3113878327core:PlantMachinery2024-12-3113878327core:ComputerEquipment2024-12-31138783272024-12-3113878327bus:PrivateLimitedCompanyLtd2025-01-012025-12-3113878327bus:SmallCompaniesRegimeForAccounts2025-01-012025-12-3113878327bus:FRS1022025-01-012025-12-3113878327bus:AuditExemptWithAccountantsReport2025-01-012025-12-3113878327bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP